Receive our newsletter – data, insights and analysis delivered to you
July 21, 2009

Exenatide Outperforms Lantus in Head-to-Head Study

Amylin Pharmaceuticals, Eli Lilly and Alkermes have announced that exenatide once weekly has been shown to provide superior glucose control when compared to Lantus in a head-to-head duration-3 study. Patients given exenatide once weekly experienced a statistically superior reduction in A1

By cms admin

Amylin Pharmaceuticals, Eli Lilly and Alkermes have announced that exenatide once weekly has been shown to provide superior glucose control when compared to Lantus in a head-to-head duration-3 study.

Patients given exenatide once weekly experienced a statistically superior reduction in A1C (a measure of average blood sugar over three months) of 1.5 percentage points from the baseline, compared to a reduction of 1.3 percentage points for Lantus after 26 weeks of treatment.

Patients treated with exenatide once weekly also showed a statistically significant difference in weight, with a mean weight loss of 5.8 pounds at 26 weeks, compared with a mean weight gain of 3.1 pounds for Lantus, a difference of 8.9 pounds between the treatments.

In addition, patients treated with exenatide once weekly reported significantly fewer episodes of confirmed hypoglycaemia.

Amylin Pharmaceuticals senior vice-president of research and development Orville G Kolterman said that exenatide once weekly outperformed Lantus in this superiority study by meeting its primary endpoint.

“Both treatment arms started with a baseline A1C of 8.3% and exenatide once weekly provided significantly greater A1C reduction, weight loss versus weight gain and fewer episodes of hypoglycaemia,” Kolterman said.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

More than 90% of patients completed the 26-week study.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU